国药股份：关于股权分置改革持续督导保荐代表人变更的公告

Group 1 - The core point of the article is the announcement by China National Pharmaceutical Group Co., Ltd. (国药股份) regarding a change in the continuous supervision of its shareholding reform project due to the retirement of the previous supervisor [2] - Liu Xiangsheng, the former supervising representative for the shareholding reform, will be replaced by Shenwan Hongyuan's representative, Lu Wenjun, who will continue to fulfill the supervisory responsibilities [2]